Quick Takeaways
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX).
- Disclosed ownership: 7.9%.
- Date of event: 31 Dec 2024.
PERCEPTIVE ADVISORS LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Perceptive Advisors LLC
- Symbol
- AMLX
- Shares outstanding
- 85,751,241 shares
- Disclosed Ownership
- 6,774,348 shares
- Ownership
- 7.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:15:06 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PERCEPTIVE ADVISORS LLC disclosed 7.9% ownership in Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 7.9% | 6,774,348 | 0 | 6,774,348 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | |
| Joseph Edelman | 7.9% | 6,774,348 | 0 | 6,774,348 | /s/ Joseph Edelman | Joseph Edelman | |
| Perceptive Life Sciences Master Fund, Ltd. | 7.9% | 6,774,348 | 0 | 6,774,348 | /s/ Joseph Edelman | Joseph Edelman, Managing Member |